Kinetics of Soluble Mediators of the Host Response in Ebola Virus Disease

Archive ouverte

Kerber, R. | Krumkamp, R. | Korva, M. | Rieger, T. | Wurr, S. | Duraffour, S. | Oestereich, L. | Gabriel, M. | Sissoko, Daouda | Anglaret, Xavier | Malvy, Denis | May, J. | Zupanc, T. A. | Munoz-Fontela, C. | Gunther, S.

Edité par CCSD ; Oxford University Press -

International audience. Background: The pathophysiology of Ebola virus disease (EVD) is still poorly understood. This study aimed at identifying soluble biomarkers that inform on disease mechanisms.Methods: Fifty-four soluble mediators of the immune, coagulation, and endothelial system were measured in baseline and follow-up samples from hospitalized patients with EVD, using Luminex technology. Cross-sectional expression levels and changes over time were correlated with outcome. Results: Levels of circulating proinflammatory cytokines and chemokines, as well as markers of endothelial dysfunction and coagulopathy, were elevated on admission to hospital in patients who died from EVD as compared to survivors. These markers further increased in patients who died and/or decreased over time in survivors. In contrast, markers of gut integrity and T-cell response were higher in survivors and increased until discharge.Conclusions: Inflammatory response, endothelial integrity, gastric tissue protection, and T cell immunity play a role in EVD pathophysiology.

Suggestions

Du même auteur

Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study

Archive ouverte | Kerber, R. | CCSD

International audience. BACKGROUND: In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients. Cycle threshold (Ct) in the Ebola virus RT-PCR and 13 ...

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

Archive ouverte | Nguyen, Thi Huyen Tram | CCSD

International audience. n 2014–2015, the JIKI trial was conducted in Guinea to test favipiravir tolerance and efficacy in patients with Ebola virus disease (EDV). The main results of the trial were previously publis...

Doing science in an emergency : outcomes and pitfalls of a clinical trial in the Ebola outbreak

Archive ouverte | Le Marcis, Frédéric | CCSD

International audience

Chargement des enrichissements...